Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian N Finck

Showing results (1-10 of 182) with videos related to

Pageof 19
Sort By:
Cardiovascular Research|October 3, 2006
The PPAR regulatory system in cardiac physiology and diseaseBrian N Finck
Cellular and Molecular Gastroenterology and Hepatology|April 4, 2022
Something to mTORC About in NASHBrian N Finck
Diabetes|November 22, 2018
Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic SteatohepatitisBrian N Finck
Diabetes|April 21, 2012
A sweet new role for ubiquitin-specific protease 2 in controlling hepatic gluconeogenesisBrian N Finck
Cellular and Molecular Gastroenterology and Hepatology|August 26, 2024
A Role for Impaired RECK Activity in Metabolic Dysfunction-associated Steatotic Liver DiseaseBrian N Finck
Current Opinion in Clinical Nutrition and Metabolic Care|June 12, 2004
The role of the peroxisome proliferator-activated receptor alpha pathway in pathological remodeling of the diabetic heartBrian N Finck
Expert Review of Cardiovascular Therapy|March 3, 2006
Effects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle?Brian N Finck
Nature Reviews. Endocrinology|June 16, 2021
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitusDaniel Ferguson, Brian N Finck
Biomed Research International|August 15, 2015
Does Diacylglycerol Accumulation in Fatty Liver Disease Cause Hepatic Insulin Resistance?Brian N Finck, Angela M Hall
The Journal of Clinical Investigation|December 16, 2024
Beyond ketosis: the search for the mechanism underlying SGLT2-inhibitor benefit continuesJustin H Berger, Brian N Finck
Pageof 19

Showing results (1-10 of 182) with videos related to

Sort By:
Pageof 19
Cardiovascular Research|October 3, 2006
The PPAR regulatory system in cardiac physiology and diseaseBrian N Finck
Cellular and Molecular Gastroenterology and Hepatology|April 4, 2022
Something to mTORC About in NASHBrian N Finck
Diabetes|November 22, 2018
Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic SteatohepatitisBrian N Finck
Diabetes|April 21, 2012
A sweet new role for ubiquitin-specific protease 2 in controlling hepatic gluconeogenesisBrian N Finck
Cellular and Molecular Gastroenterology and Hepatology|August 26, 2024
A Role for Impaired RECK Activity in Metabolic Dysfunction-associated Steatotic Liver DiseaseBrian N Finck
Current Opinion in Clinical Nutrition and Metabolic Care|June 12, 2004
The role of the peroxisome proliferator-activated receptor alpha pathway in pathological remodeling of the diabetic heartBrian N Finck
Expert Review of Cardiovascular Therapy|March 3, 2006
Effects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle?Brian N Finck
Nature Reviews. Endocrinology|June 16, 2021
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitusDaniel Ferguson, Brian N Finck
Biomed Research International|August 15, 2015
Does Diacylglycerol Accumulation in Fatty Liver Disease Cause Hepatic Insulin Resistance?Brian N Finck, Angela M Hall
The Journal of Clinical Investigation|December 16, 2024
Beyond ketosis: the search for the mechanism underlying SGLT2-inhibitor benefit continuesJustin H Berger, Brian N Finck
Pageof 19